SCHEMBL6184580

SCHEMBL6184580

CCOC(=O)C(C)Cc1ccc(-c2cccc(CNCC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.43
EPHX2 P34913 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PGGT1B P53609 1/20 0.41
MME P08473 1/20 0.41
MMEL1 Q495T6 1/20 0.41
FFAR1 O14842 3/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
TPH1 P17752 1/20 0.40
OPRK1 P41145 1/20 0.40
PPARA Q07869 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
MMP8 P22894 1/20 0.40
HDAC1 Q13547 1/20 0.39
F2 P00734 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6156035 0.89 TPH1 (0.48) PPARGEPHX2SMN1; SMN2TP53FNTA
SCHEMBL6184063 0.88 MME (0.49) FNTAFNTBPGGT1BMMEMMEL1
SCHEMBL6155054 0.83 CTSS (0.52) EPHX2TP53MEN1KMT2A
SCHEMBL3439079 0.83 TP53 (0.41) PPARGTP53FNTAFNTBPGGT1B
SCHEMBL3439078 0.83 TP53 (0.41) PPARGTP53FNTAFNTBPGGT1B
SCHEMBL6155896 0.82 PPARG (0.44) PPARGSMN1; SMN2TP53MEN1KMT2A
SCHEMBL6155899 0.82 PPARG (0.44) PPARGSMN1; SMN2TP53MEN1KMT2A
SCHEMBL2853890 0.82 PPARG (0.48) PPARGPPARA
SCHEMBL6156263 0.82 PPARG (0.48) PPARGPPARA
SCHEMBL6158603 0.82 TPH1 (0.49) FNTAFNTBPGGT1BTPH1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP claimed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US claimed
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD PPARG 1/4885EPHX2 1174/4885SMN1; SMN2 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.